Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA ...

Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company ...

A new generation of shell-less incubation technology supports complete avian embryo development without supplemental oxygen, ...

Ustekinumab BS 45 mg Syringe for S.C. Injection「NIPRO」 is now available in Japan, after its listing under the National Health Insurance (NHI) Drug Price StandardMarks first launch in Japan through ...

BFA Law is investigating whether Badger Meter committed securities fraud relating to its representations about demand for the company’s products and its prospects for growth.NEW YORK--(BUSINESS WIRE)- ...

Landmark project rapidly deploys over 200 of Antora’s thermal batteries to deliver firm energy and enhance the competitiveness of POET’s Big Stone City plant BIG STONE CITY, S.D.--(BUSINESS ...

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer ...

Fast-growth biopharma startup develops groundbreaking product pipeline to target oral health epidemicMINNEAPOLIS--(BUSINESS WIRE)--#periodontaldisease--Twin Cities-based ProEncia Biotechnology, a ...

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated ...

Safety Monitoring Committee (SMC) recommended initiation of Part B of the peanut allergy trialFunding secured for follow-on tree (Fagales) pollen program MY010Mabylon AG, a leader in the discovery and ...

Site will serve as company’s new headquarters and expands capacity and capabilities for induced pluripotent stem cell ...

The oversubscribed second fund plans to deploy capital across 12 to 15 companies, with individual investments of €20 to €50 million focused on US and global market expansionPARIS & SAN ...